Synthetic peptide dendrimers block the development and expression of experimental allergic encephalomyelitis

Keith W. Wegmann, Cynthia R. Wagner, Ruth Whitham, David J. Hinrichs

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Multiple Ag peptides (MAPs) containing eight proteolipid protein (PLP) 139-151 peptides arranged around a dendrimeric branched lysine core were used to influence the expression and development of relapsing experimental allergic encephalomyelitis (EAE) in SJL mice. The PLP139-151 MAPs were very efficient agents in preventing the development of clinical disease when administered after immunization with the PLP139-151 monomeric encephalitogenic peptide in CFA. The treatment effect with these MAPs was peptide specific; irrelevant multimeric peptides such as guinea pig myelin basic protein GPBP72-84 MAP (a dendrimeric octamer composed of the 72-84 peptide) and PLP178-191 MAP (a dendrimeric octamer composed of the PLP178-191 peptide) had no treatment effect on PLP 139-151-induced EAE. PLP139-151 MAP treatment initiated after clinical signs of paralysis also altered the subsequent course of EAE; it limited developing signs of paralysis and effectively limited the severity and number of disease relapses in MAP-treated mice over a 60-day observation period. PLP139-151 MAP therapy initiated before disease onset acts to limit the numbers of Th17 and IFN-γ-producing cells that enter into the CNS. However, Foxp3+ cells entered the CNS in numbers equivalent for nontreated and PLP139-151 MAP-treated animals. The net effect of PLP139-151 MAP treatment dramatically increases the ratio of Foxp3+ cells to Th17 and IFN-γ-producing cells in the CNS of PLP139-151 MAP-treated animals.

Original languageEnglish (US)
Pages (from-to)3301-3309
Number of pages9
JournalJournal of Immunology
Volume181
Issue number5
StatePublished - Sep 1 2008

Fingerprint

Dendrimers
Autoimmune Experimental Encephalomyelitis
Peptides
Paralysis
Therapeutics
Th17 Cells
Myelin Basic Protein

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Synthetic peptide dendrimers block the development and expression of experimental allergic encephalomyelitis. / Wegmann, Keith W.; Wagner, Cynthia R.; Whitham, Ruth; Hinrichs, David J.

In: Journal of Immunology, Vol. 181, No. 5, 01.09.2008, p. 3301-3309.

Research output: Contribution to journalArticle

Wegmann, Keith W. ; Wagner, Cynthia R. ; Whitham, Ruth ; Hinrichs, David J. / Synthetic peptide dendrimers block the development and expression of experimental allergic encephalomyelitis. In: Journal of Immunology. 2008 ; Vol. 181, No. 5. pp. 3301-3309.
@article{d597d80d7cf242ad968d5ccf08eee0f1,
title = "Synthetic peptide dendrimers block the development and expression of experimental allergic encephalomyelitis",
abstract = "Multiple Ag peptides (MAPs) containing eight proteolipid protein (PLP) 139-151 peptides arranged around a dendrimeric branched lysine core were used to influence the expression and development of relapsing experimental allergic encephalomyelitis (EAE) in SJL mice. The PLP139-151 MAPs were very efficient agents in preventing the development of clinical disease when administered after immunization with the PLP139-151 monomeric encephalitogenic peptide in CFA. The treatment effect with these MAPs was peptide specific; irrelevant multimeric peptides such as guinea pig myelin basic protein GPBP72-84 MAP (a dendrimeric octamer composed of the 72-84 peptide) and PLP178-191 MAP (a dendrimeric octamer composed of the PLP178-191 peptide) had no treatment effect on PLP 139-151-induced EAE. PLP139-151 MAP treatment initiated after clinical signs of paralysis also altered the subsequent course of EAE; it limited developing signs of paralysis and effectively limited the severity and number of disease relapses in MAP-treated mice over a 60-day observation period. PLP139-151 MAP therapy initiated before disease onset acts to limit the numbers of Th17 and IFN-γ-producing cells that enter into the CNS. However, Foxp3+ cells entered the CNS in numbers equivalent for nontreated and PLP139-151 MAP-treated animals. The net effect of PLP139-151 MAP treatment dramatically increases the ratio of Foxp3+ cells to Th17 and IFN-γ-producing cells in the CNS of PLP139-151 MAP-treated animals.",
author = "Wegmann, {Keith W.} and Wagner, {Cynthia R.} and Ruth Whitham and Hinrichs, {David J.}",
year = "2008",
month = "9",
day = "1",
language = "English (US)",
volume = "181",
pages = "3301--3309",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Synthetic peptide dendrimers block the development and expression of experimental allergic encephalomyelitis

AU - Wegmann, Keith W.

AU - Wagner, Cynthia R.

AU - Whitham, Ruth

AU - Hinrichs, David J.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Multiple Ag peptides (MAPs) containing eight proteolipid protein (PLP) 139-151 peptides arranged around a dendrimeric branched lysine core were used to influence the expression and development of relapsing experimental allergic encephalomyelitis (EAE) in SJL mice. The PLP139-151 MAPs were very efficient agents in preventing the development of clinical disease when administered after immunization with the PLP139-151 monomeric encephalitogenic peptide in CFA. The treatment effect with these MAPs was peptide specific; irrelevant multimeric peptides such as guinea pig myelin basic protein GPBP72-84 MAP (a dendrimeric octamer composed of the 72-84 peptide) and PLP178-191 MAP (a dendrimeric octamer composed of the PLP178-191 peptide) had no treatment effect on PLP 139-151-induced EAE. PLP139-151 MAP treatment initiated after clinical signs of paralysis also altered the subsequent course of EAE; it limited developing signs of paralysis and effectively limited the severity and number of disease relapses in MAP-treated mice over a 60-day observation period. PLP139-151 MAP therapy initiated before disease onset acts to limit the numbers of Th17 and IFN-γ-producing cells that enter into the CNS. However, Foxp3+ cells entered the CNS in numbers equivalent for nontreated and PLP139-151 MAP-treated animals. The net effect of PLP139-151 MAP treatment dramatically increases the ratio of Foxp3+ cells to Th17 and IFN-γ-producing cells in the CNS of PLP139-151 MAP-treated animals.

AB - Multiple Ag peptides (MAPs) containing eight proteolipid protein (PLP) 139-151 peptides arranged around a dendrimeric branched lysine core were used to influence the expression and development of relapsing experimental allergic encephalomyelitis (EAE) in SJL mice. The PLP139-151 MAPs were very efficient agents in preventing the development of clinical disease when administered after immunization with the PLP139-151 monomeric encephalitogenic peptide in CFA. The treatment effect with these MAPs was peptide specific; irrelevant multimeric peptides such as guinea pig myelin basic protein GPBP72-84 MAP (a dendrimeric octamer composed of the 72-84 peptide) and PLP178-191 MAP (a dendrimeric octamer composed of the PLP178-191 peptide) had no treatment effect on PLP 139-151-induced EAE. PLP139-151 MAP treatment initiated after clinical signs of paralysis also altered the subsequent course of EAE; it limited developing signs of paralysis and effectively limited the severity and number of disease relapses in MAP-treated mice over a 60-day observation period. PLP139-151 MAP therapy initiated before disease onset acts to limit the numbers of Th17 and IFN-γ-producing cells that enter into the CNS. However, Foxp3+ cells entered the CNS in numbers equivalent for nontreated and PLP139-151 MAP-treated animals. The net effect of PLP139-151 MAP treatment dramatically increases the ratio of Foxp3+ cells to Th17 and IFN-γ-producing cells in the CNS of PLP139-151 MAP-treated animals.

UR - http://www.scopus.com/inward/record.url?scp=51549118116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51549118116&partnerID=8YFLogxK

M3 - Article

C2 - 18714002

AN - SCOPUS:51549118116

VL - 181

SP - 3301

EP - 3309

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -